Effect of Chamomile tea consumption in the treatment of depressed patients with type 2 diabetes

Phase 2

• Conditions: depression.; Depressive episode, Recurrent depressive disorder; F32, F33

• Registration Number: IRCT2014112820132N1
• Lead Sponsor: Shahid Sadooghi University of Medical Sciences and Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

Those aged between 60-30 years with mild to moderate depression (Beck test score of 30-11). no disorders and diseases of the kidney, liver, heart, thyroid, bleeding disorders and malignancies, autoimmune diseases, and degenerative diseases of the central nervous system as the express themselves, no history of hospitalization for mental illness, not using nutritional and antioxidant supplementation and sedative and diuretics during the last 3 months, diabetes mellitus type 2 (minimum 5 and maximum 15-year history of diabetes), and usage of blood glucose lowering drugs, patients with dyslipidemia who the usual treatment continue, Pregnant and lactating absence and lack of events such as job loss, divorce or death of their relatives during the last 3 months. Exclusion criteria: having allergy to chamomile, major depression (Beck test score greater than 30), which requires special treatment, , people that during the interview noticed Thoughts of suicide, self-injury and a history of such in them and preferring not to drink tea.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression. Timepoint: Baseline, after 6 weeks of intervention and At the end of the intervention. Method of measurement: Beck Depression Inventory.

Secondary Outcome Measures

Name	Time	Method
HbA1c. Timepoint: Baseline and after 12 weeks of intervention. Method of measurement: Chromatography.;LDL_C. Timepoint: Baseline and after 12 weeks of intervention. Method of measurement: Freidwald’s formula.;HDL_C. Timepoint: Baseline and after 12 weeks of intervention. Method of measurement: Colorimetry.;TG. Timepoint: Baseline and after 12 weeks of intervention. Method of measurement: Colorimetry.;TC. Timepoint: Baseline and after 12 weeks of intervention. Method of measurement: Colorimetry.;TAC. Timepoint: Baseline and after 12 weeks of intervention. Method of measurement: Reduction DPPH.;MDA. Timepoint: Baseline and after 12 weeks of intervention. Method of measurement: Thiobarbituric Acid.